We thank Dr. Murray for his interest in our work and comments1,2. We completely agree that establishing safety of immunosuppressive pharmacotherapy is of paramount importance, especially when treating older patients given the increased susceptibility to infection. Although our study is one of the largest evaluating impact of early combined immunosuppression vs. conventional management over a 2-year period, it was not adequately powered to address safety of different therapies.2 In a systematic review, Borren and Ananthakrishnan estimated that the odds of serious infections and malignancy were 2.3 to 3.1-times higher in older patients treated with biologic agents, as compared to younger patients treated with biologic agents.3 However, as noted by Dr. Murrary, within older age patients with inflammatory bowel diseases, specific patient attributes may be associated with increased risk of disease-related vs. treatment-related complications, and for others risk of extra-intestinal, non-inflammatory bowel disease-related complications may dominate.4 Treatment would ideally be tailored to specific patient risk attributes, including both risk of disease-related vs. treatment-related complications. Future studies need to evaluate the appropriate older patients for whom a strategy of early combined immunosuppression would be effective and safe. Furthermore, these should also be evaluated in the context of novel therapies which have differing safety profiles to anti-TNF therapy.
Acknowledgments
Funding: Research reported in this publication was supported by the American College of Gastroenterology Junior Faculty Development Award #144271, Crohn’s and Colitis Foundation Career Development Award #404614, and the National Institute of Diabetes and Digestive and Kidney Diseases K23DK117058 to Siddharth Singh. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Footnotes
Disclosures: Siddharth Singh: Research support from Pfizer and AbbVie, consulting fees from AbbVie, outside the submitted work; Vipul Jairath: Consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena pharmaceuticals, Genetech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Robarts Clinical Trials, Topivert, Celltrion; speaker’s fees from Takeda, Janssen, Shire, Ferring, Abbvie, Pfizer
REFERENCES:
- 1.Murray CDR. Editorial: Combination immunosuppressive therapy to treat Crohn’s disease – ready for all age groups? Aliment Pharmacol Ther 2019; in press. [DOI] [PubMed] [Google Scholar]
- 2.Singh S, Stitt LW, Zou G, et al. Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT. Aliment Pharmacol Ther 2019. doi: 10.1111/apt.15214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Borren NZ, Ananthakrishnan AN. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2019; doi: 10.1016/j.cgh.2018.12.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2018;24:916–9235. [DOI] [PubMed] [Google Scholar]